Skip to content
DataLookout
Menu

IMPALA ERASNCT07224711

The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 31, 2026 to Oct 26, 2026
    • Site details revised
  2. Notable Eligibility criteria expanded, about 14 words
    • Interventions modified
    • Secondary endpoints: details revised at 3 of 7 entries
  3. Notable Start date: Jul 1, 2026 to Oct 31, 2026
    • Primary and study completion pushed from May 30, 2028 to Oct 31, 2028
    v3
  4. Notable Start date: Jun 1, 2026 to Jul 1, 2026
    • Eligibility criteria shortened, about 12 words
    • Primary endpoints: 1 to 2
    • Study title revised
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Case Mix Index-Adjusted Resource Length of Stay (CARLOS)
Timeframe: Hospital admission to discharge (usually 4-7 days)
Total Inpatient opioid consumption
Timeframe: Start of study medication to 72 hours

Secondary (7)

Resource Length Of Stay (RLOS)
Case Mix Index
Total consumption of inpatient opioids
Pain Visual Analog Score
Incidence of surgical outcomes
Show 2 moreShow less
Incidence of treatment side effects
Incidence of meeting early discharge milestones

Arms and interventions

LIdocaineActive comparator

Participants randomized to receive 1.5 mg /kg bolus of 0.8% lidocaine Hydrochoride (HCL) in dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be followed by continuous IV infusion of 2 mg/minute of 0.8% lidocaine HCl in D5W intraoperatively with weight-based gradated dosing postoperatively (1-2 mg/minute)

PlaceboPlacebo comparator

Participants randomized to receive dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be equivalent in volume to the lidocaine arm. The bolus will be followed by continuous IV infusion intraoperatively and then up to 48 hours. The continuous IV infusion will be equivalent in volume and rate to the lidocaine arm.

Drugs: Lidocaine HCl 0.8% in D5W, Dextrose 5% in water

Sites

1 site in 1 country

  • Vanderbilt University Medical CenterNashville, Tennessee, United States